Page 16 - Viral Vector News Today

A new bioRxiv* preprint study led by Michelle Monje of Stanford University in California finds that a mild COVID-19 infection can produce long-term neurological damage. Persistent cognitive complications are one of many symptoms of long COVID, and the latest results suggest the severity of COVID-19 induced brain fog is similar to cancer’s “chemobrain.”

Researchers determine whether sequences within SARS-CoV-2 could lead to an immune response to autoantigens associated with autoimmune myocarditis.

Healthcare investors, GHO Capital Partners LLP, have invested in Scotland based, RoslinCT, a contract development and manufacturing organization (CDMO) focused on advanced cell therapies.

MRNA Treatment  Market Outlook – Post Covid-19 Scenario by 2027

MRNA Treatment  Market Outlook – Post Covid-19 Scenario by 2027

Dublin, Jan. 07, 2022 (GLOBE NEWSWIRE) -- The "Technology Developments in Viral Vector Manufacturing for Cell and Gene Therapies" report has been added...

/PRNewswire/ -- GPB Scientific, Inc., a key enabling technology company for cell therapy manufacturing, announced the hiring of Gaurav Vij and Joan Haab, PhD,...

A new study did not conclusively correlate the incidence of myocarditis or pericarditis with mRNA vaccination against SARS-CoV-2.

Global Viral and Non-Viral Vector Manufacturing Market to Reach $27. 03 Billion by 2031. ...

A recent review article discusses recent advances in protein-based nanoparticle vaccines against SARS-CoV-2.